Off-label use of rituximab in dermatology: pemphigus treatment*
نویسندگان
چکیده
Since its approval in 1997 by the FDA (United States Food and Drug Administration), rituximab has been used for certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Nevertheless, over the past 14 years, many case reports have demonstrated the efficacy of off-label rituximab in several dermatological inflammatory conditions. This study describes two cases of pemphigus vulgaris and two cases of pemphigus foliaceous that were treated with rituximab at 375 mg/m2 once a week for 4 weeks, and that responded well to treatment.
منابع مشابه
Evaluation of the efficacy and safety of rituximab in patients with refractory pemphigus vulgaris
Background: Recently, rituximab has been successfully used for the treatment of pemphigus family, the main subtype of which is pemphigus vulgaris (PV). The aim of this study was to determine the efficacy and safety of rituximab in refractory PV. Methods: In an observational study extending from November 2014 to February 2016, 30 patients with refractory PV were treated with rituximab. Response ...
متن کاملRituximab therapy in pemphigus and other autoantibody-mediated diseases
Rituximab, a monoclonal antibody targeting the B cell marker CD20, was initially approved in 1997 by the United States Food and Drug Administration (FDA) for the treatment of non-Hodgkin lymphoma. Since that time, rituximab has been FDA-approved for rheumatoid arthritis and vasculitides, such as granulomatosis with polyangiitis and microscopic polyangiitis. Additionally, rituximab has been used...
متن کاملShifting Focus in the Therapeutics of Immunobullous Disease
Therapeutics of autoimmune bullous disease has seen a major shift of focus from more global immunosuppression to targeted immunotherapy. Anti CD 20 monoclonal antibody Rituximab revolutionized the therapeutics of autoimmune bullous disease particularly pemphigus. Though it is still being practiced off-label, evidences in the form of RCT and meta analysis are now available. Other novel anti CD 2...
متن کاملIntermediate doses of rituximab used as adjuvant therapy in refractory pemphigus.
BACKGROUND Rituximab, a monoclonal anti-CD20 antibody, has been used with encouraging results in pemphigus. We describe herein refractory cases of pemphigus vulgaris (n = 23) and pemphigus foliaceus (n = 1) treated with rituximab in addition to steroids and immunosuppressants. AIMS To assess the response to treatment, the duration of clinical remission, serology of the response and adverse ef...
متن کاملPlica neuropathica: different etiologies in two cases.
Systemic corticosteroids are the treatment of choice for pemphigus vulgaris. Immunosuppressive agent (azathioprine, cyclophosphamide) could be added for patients with severe disease that cannot be controlled by corticosteroids alone or to reduce the dose of corticosteroids.[5] However, immunosuppressants continue to have the complications of systemic infections. Successful use of rituximab ther...
متن کامل